Investigational drug · Phase 3
Jaktinib Hydrochloride
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Ankylosing Spondylitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
0 still active
All registered trials
23
Any phase or sponsor naming "Jaktinib Hydrochloride"
First trial start
2022
Jul 14, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Jaktinib Hydrochloride", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Ankylosing Spondylitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Ankylosing spondylitis · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Jaktinib Hydrochloride" as an intervention, largest first.
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT05526222 · 443 participants · Start Jul 14, 2022 · Primary completion Aug 5, 2025
Drug: Jaktinib Hydrochloride Tablet · For: Atopic Dermatitis
Sites: Beijing, China; Nanjing, China
- A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT05676242 · 207 participants · Start Jan 11, 2023 · Primary completion Mar 12, 2026
Drug: Jaktinib Hydrochloride Tablet · For: Atopic Dermatitis
Sites: Beijing, China; Nanjin, China
- Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic DermatitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT04539639 · 166 participants · Start Dec 2, 2020 · Primary completion May 19, 2022
Drug: Jaktinib; Jaktinib and 2 more · For: Atopic Dermatitis
Sites: Changsha, China
- A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia AreataPivotal-lookingStatus unknown
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT04445363 · 160 participants · Start Aug 12, 2020 · Primary completion Dec 1, 2024
Drug: Jaktinib hydrochloride cream; Placebo · For: Alopecia Areata(AA)
Sites: Changsha, China
- An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaPivotal-lookingStatus unknown
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT05686629 · 120 participants (planned) · Start Apr 2024 · Primary completion Feb 2025
Drug: Jaktinib hydrochloride tablets · For: Novel COVID-19-Infected Pneumonia
Sites: Chengdu, China
- Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.Pivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT03886415 · 118 participants · Start Jan 8, 2019 · Primary completion Feb 2, 2021
Drug: Jaktinib hydrochloride tablets · For: Myelofibrosis
Sites: Hangzhou, China
- Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia AreataPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT04034134 · 111 participants · Start Nov 18, 2019 · Primary completion Nov 26, 2021
Drug: Jaktinib Hydrochloride Tablets; Jaktinib Hydrochloride Tablets and 1 more · For: Alopecia Areata
Sites: Chongqing, China; Changsha, China
- Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing SpondylitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT04507659 · 108 participants · Start Dec 1, 2020 · Primary completion Aug 2, 2022
Drug: Jaktinib Hydrochloride Tablets; Jaktinib Hydrochloride Tablets and 1 more · For: Ankylosing Spondylitis
Sites: Shanghai, China
- Jaktinib Hydrochloride Cream For Atopic DermatitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT04435392 · 107 participants · Start Oct 14, 2020 · Primary completion Sep 8, 2022
Drug: Jaktinib Hydrochloride Cream; Placebo · For: Atopic Dermatitis
Sites: Changsha, China
- Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk MyelofibrosisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT04617028 · 105 participants · Start Feb 5, 2021 · Primary completion Oct 18, 2023
Drug: Jaktinib; Placebo to match Hydroxycarbamide and 2 more · For: Myelofibrosis
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Correction: Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.
· RMD Open 2025
- Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.
Wang J, Bao C, Dai Q, et al. · RMD Open 2025
- Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.
Meng X, Ling Y, Zhang L, et al. · Biosci Trends 2020
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.